TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36538259
Drug: Mitazalimab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitazalimab (600 μg/kg)
Study: 36538259
Drug: Mitazalimab (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitazalimab (2000 μg/kg)
Study: 36538309
Drug: ICE care
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE care model (risk-stratified, multidisciplinary intervention combining physical therapy, health coach counseling, and specialist consultation)
Study: 36538309
Drug: Individualized postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized postural therapy (IPT, combining physical therapy with self-efficacy and self-management)
Study: 36538328
Drug: 12 weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weekly, 30-minute virtual health coach sessions + 11 weekly cooking videos and associated home-delivered groceries
Study: 36538409
Drug: ExPlas (exercise-trained
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPlas (exercise-trained plasma) transfusion from young, healthy, fit adults, administered once a month for 4 months.
Study: 36538782
Drug: Soticlestat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat (100 mg twice daily, titrated up to 300 mg twice daily)
Study: 36539568
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula therapy
Study: 36539711
Drug: 15 mg/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/hour intravenous clazosentan
Study: 36539734
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) group
Study: 36539736
Drug: Chlorhexidine mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthrinse (0.12% chlorhexidine gluconate, gargled for 1 minute with 100 mL)
Study: 36539810
Drug: 40-mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg dose of doxycycline
Study: 36539810
Drug: 200-mg antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg antibiotic dose of doxycycline
Study: 36540016
Drug: Aspiration during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration during intramuscular injection
Study: 36540016
Drug: No aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspiration during intramuscular injection
Study: 36541390
Drug: Heart-shaped intrauterine
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart-shaped intrauterine balloon inserted immediately after hysteroscopic adhesiolysis, left in place for 7 days under antibiotic prophylaxis.
Study: 36542081
Drug: CF1 (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF1 (340 µg dexamethasone)
Study: 36542081
Drug: CF2 (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF2 (340 µg dexamethasone)
Study: 36542086
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: avalglucosidase alfa 20 mg/kg every other week for 6 months
Study: 36542086
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: avalglucosidase alfa 40 mg/kg every other week for 6 months
Study: 36542086
Drug: alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: alglucosidase alfa (current stable dose) for 6 months
Study: 36542261
Drug: Continuous terlipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terlipressin infusion (CONI), 4 mg/24 h for 5 days
Study: 36542261
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus terlipressin (BOL), 2 mg every 4 h
Study: 36542261
Drug: Continuous terlipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terlipressin infusion (CONI)
Study: 36542261
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus terlipressin (BOL)
Study: 36542308
Drug: PVO-OS (0.025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVO-OS (0.025, 0.05, or 0.10 mg/mL)
Study: 36542382
Drug: Thrice-weekly structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly structured exercise
Study: 36542382
Drug: Once-weekly structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly structured exercise
Study: 36542826
Drug: Lisocabtagene maraleucel
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisocabtagene maraleucel (liso-cel) - 100 × 10^6 chimeric antigen receptor-positive T cells
Study: 36542826
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) - 3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders
Study: 36543503
Drug: 7-day ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day ECG patch screening
Study: 37040116
Drug: Lecanemab 10
Normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab 10 mg/kg biweekly
Study: 36544211
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of soybeans and flaxseeds (~ 200 mg of phytoestrogens) until surgery (approximately 6 weeks)
Study: 36545256
Drug: Thiopurine 6-thioguanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurine 6-thioguanine (6TG) treatment
Study: 36545312
Drug: Ticagrelor treatment
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor treatment in patients with CYP3A4*22 and CYP3A5 genotypes
Study: 36546479
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (4 μg/kg initial dose, followed by 2 μg/kg if needed)
Study: 37660704
Drug: Weekly dupilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dupilumab (300 mg)
Study: 37660704
Drug: Dupilumab every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab every 2 weeks (300 mg)
Study: 36546626
Drug: Lentiviral gene-corrected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral gene-corrected autologous CD34+ cells infusion
Study: 36546659
Drug: Adagrasib monotherapy
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib monotherapy (600 mg orally twice daily)
Study: 36546659
Drug: Adagrasib in
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib in combination with cetuximab (initial loading dose of 400 mg/m², followed by 250 mg/m² weekly or 500 mg/m² every 2 weeks)
Study: 36547147
Drug: Linac-based SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linac-based SBRT on the prostate bed, total dose of 32.5 Gy in five fractions every other day.
Study: 36547262
Drug: Posterior quadratus
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior quadratus lumborum block (QLB) with 3.75 mg/ml ropivacaine 20 ml/side
Study: 36547975
Drug: Oral β-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral β-glucan during the first 5 weeks of vaccine priming (group 2)
Study: 36547975
Drug: GD2/GD3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GD2/GD3 vaccine without β-glucan (group 1)
Study: 36547975
Drug: Oral β-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral β-glucan during vaccine boost (both groups)
Study: 36547975
Drug: Anti-GD2 IgG1
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-GD2 IgG1 titer of 230 ng/mL or greater by week 8
Study: 36547975
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of antibody titer with dectin-1 SNP
Study: 36547975
Drug: Vaccine-related toxic
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-related toxic effects
Study: 36548225
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of any active antibiotic
Study: 36548225
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of any active antibiotic
Study: 36548338
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care Exercise Prescription (UCEP)
Study: 36548444
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (single dose of praziquantel)
Study: 36548444
Drug: Intense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense treatment (4 repeated doses of praziquantel at 2-week intervals)
Study: 36549308
Drug: Tenecteplase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.25 mg per kg of bodyweight, maximum 25 mg)
Study: 36549320
Drug: Levofloxacin-based sequential
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based sequential quadruple therapy for 14 days (EAML14); esomeprazole 40 mg and amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, metronidazole 500 mg, and levofloxacin 250 mg for 7 days, all twice-daily.
Study: 36549320
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy for 10 days (BQ10); esomeprazole 40 mg twice daily, bismuth tripotassium dicitrate 300 mg four times a day, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day.
Study: 36549320
Drug: Levofloxacin-based sequential
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based sequential quadruple therapy (EAML14) and Bismuth-based quadruple therapy (BQ10)
Study: 36549723
Drug: Pharmacist-conducted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-conducted medication reconciliation
Study: 36549740
Drug: Free access
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free access to a comprehensive list of essential medicines for 24 months
Study: 36549786
Drug: Home-based inspiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based inspiratory muscle training (IMT) for 12 weeks, training twice daily using a threshold inspiratory muscle trainer
Study: 36549898
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily, increased to 20 mg daily after 4 weeks if no toxicity
Study: 36550428
Drug: Two additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two additional cycles of Lutathera® (7.4 GBq infusion each, separated by 8 weeks)
Study: 36550428
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (active surveillance)
Study: 36550466
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine refusal
Study: 36550559
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL crystalloid fluid bolus (FB) administered over 30 min
Study: 36550559
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL crystalloid fluid bolus (FB)
Study: 36550562
Drug: Clazakizumab (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (12.5 mg subcutaneous once every 4 weeks)
Study: 36550683
Drug: Trastuzumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and Irinotecan (120 mg/m2 days 1 and 8 every 3 weeks)
Study: 36551677
Drug: SAMITAL granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMITAL granules for oral suspension (20 mL, four times daily)
Study: 36551677
Drug: SAMITAL granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMITAL granules for oral suspension
Study: 36553294
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for SDB
Study: 36553294
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for SDB
Study: 36554581
Drug: Intravenous route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous route for postoperative pain management
Study: 36554820
Drug: Short-term psychoanalytic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychoanalytic therapy with Johanna (good outcome)
Study: 36554820
Drug: Short-term psychoanalytic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychoanalytic therapy with Sonja (poor outcome)
Study: 36554860
Drug: Traditional form
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional form of therapy (Control)
Study: 36555933
Drug: Placebo→Rituximab 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo→Rituximab 1000 mg
Study: 36555933
Drug: Placebo→Rituximab 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo→Rituximab 500 mg
Study: 36560966
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C pressurized intraperitoneal aerosolized chemotherapy (MMC-PIPAC) combined with systemic chemotherapy (FOLFIRI)
Study: 36561174
Drug: Ivermectin 600
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 600 μg/kg daily for 6 days
Study: 36561174
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 6 days
Study: 36561714
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (E-Stim) for 1 hour daily for up to 14 days on both gastrocnemius muscles (GNMs)
Study: 36561723
Drug: Prior use
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior use of non-steroidal anti-inflammatory drugs
Study: 36561857
Drug: Initial Medication
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial Medication Adherence (IMA) intervention
Study: 36562136
Drug: MA (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (160 mg oral daily)
Study: 36562136
Drug: MA +
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MA + LNG-IUS (160 mg oral daily + LNG-IUS)
Study: 36562609
Drug: Combined platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined platinum-based chemotherapy with cetuximab treatment
Study: 36562831
Drug: Metformin arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin arm (n=15) - received letrozole 2.5 mg/day plus metformin (2000±500 mg/day)
Study: 36562831
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (n=15) - received letrozole 2.5 mg/day
Study: 36562831
Drug: Lean arm
Normalized name: Lophophytum leandrii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean arm (n=15) - received letrozole 2.5 mg/day
Study: 36562873
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of elamipretide
Study: 36563086
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TEST; 200 mg·wk -1)
Study: 36564033
Drug: Higher urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher urinary lithium excretion
Study: 36564099
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2)
Study: 36564099
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2) in patients with high mesothelin expression
Study: 36564123
Drug: placebo (switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (switching to guselkumab 100 mg at week 24)
Study: 36564123
Drug: non-biological standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-biological standard of care
Study: 36564126
Drug: Intratumoral V937
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral V937 plus intravenous ipilimumab 3 mg/kg Q3W for four doses starting on day 22.
Study: 36564274
Drug: AS37 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS37 adjuvanted vaccine
Study: 36564274
Drug: Licensed alum-adjuvanted
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed alum-adjuvanted meningococcal serogroup C (MenC-CRM) vaccine
Study: 36564395
Drug: Milvexian (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (100 mg)
Study: 36564395
Drug: Milvexian (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (100 mg) and Rifampin (600 mg)
Study: 36564955
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily for 12 weeks
Study: 36565044
Drug: Conventional endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional endodontic treatment (control group)
Study: 36565044
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (PRP and conventional treatment)
Study: 36566079
Drug: Lenacapavir (927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily tenofovir alafenamide (25 mg) (group 1)
Study: 36566079
Drug: Lenacapavir (927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily bictegravir (75 mg) (group 2)
Study: 36566079
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily lenacapavir (600 mg on days 1 and 2, followed by 50 mg daily) with emtricitabine (200 mg) and tenofovir alafenamide (25 mg) (group 3)
Study: 36566079
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) (group 4)
Study: 36566186
Drug: Postoperative albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative albumin infusion
Study: 36566186
Drug: Postoperative albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative albumin infusion in patients with preoperative albumin level < 40 g/L
Study: 36566186
Drug: Postoperative albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative albumin infusion in patients with duration of surgery ≥ 3 h
Study: 36566202
Drug: DDEA 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 2.32% gel applied twice daily (BID)
Study: 36566202
Drug: DDEA 1.16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 1.16% gel applied four times daily (QID)
Study: 36566266
Drug: BRAF-MEK inhibitors
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF-MEK inhibitors
Study: 36566266
Drug: Advanced melanoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced melanoma stage, melanoma systemic therapies
Study: 36566274
Drug: Oral GABA
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GABA twice-daily (n=41)
Study: 36566274
Drug: Oral GABA
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GABA plus two-doses GAD-alum (n=25)
Study: 36566344
Drug: AK111 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK111 75 mg
Study: 36566344
Drug: AK111 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK111 150 mg
Study: 36566344
Drug: AK111 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK111 300 mg
Study: 36566344
Drug: AK111 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK111 450 mg
Study: 36567076
Drug: e-RPT (web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-RPT (web-based relapse prevention therapy)
Study: 36567076
Drug: face-to-face RPT
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: face-to-face RPT (traditional relapse prevention therapy)
Study: 36567211
Drug: Post-TCR treatments
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab); median treatment duration 3.3 months
Study: 36567211
Drug: Post-TCR treatments
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab)
Study: 36568239
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks intravenously until disease progression, unacceptable toxicity, or withdrawal.
Study: 36568250
Drug: Azacitidine (75mg/m2/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75mg/m2/d on days 1-5 subcutaneous) combined with Homoharringtonine (HHT 2mg/m2/d on days 4-8 intravenous over 3 hours), Idarubicin (6mg/m2/d on days 4-6 intravenous), and Cytarabine (100mg/m2/d on days 4-10 intravenous)
Study: 36568414
Drug: Intravenous ACBMNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ACBMNC infusion (targeted at 5 × 10^7 cells)
Study: 36568559
Drug: Non-albuminuric CKD
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-albuminuric CKD with eGFR <45 mL/min/1.73 m²
Study: 36568559
Drug: Non-albuminuric CKD
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-albuminuric CKD with eGFR ≥60 mL/min/1.73 m²
Study: 36568789
Drug: WISER intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WISER intervention (Web-based Implementation for the Science of Enhancing Resilience), delivered daily for 10 days.